Next-Generation Antibody Therapeutics Market Outlook Highlights Strategic Opportunities Across The Industry

The next-generation antibody therapeutics market is on the brink of significant expansion, driven by innovative technologies and increasing demand for targeted medical treatments. As advancements continue to reshape healthcare, this market is set to witness substantial growth and diversification by 2030.

Forecasted Market Size and Growth Trajectory of the Next-Generation Antibody Therapeutics Market
The value of the next-generation antibody therapeutics market is anticipated to rise sharply, reaching $12.63 billion by 2030 with a compound annual growth rate (CAGR) of 10.9%. This robust growth is fueled by breakthroughs in antibody engineering, a rising need for precise therapies, a surge in chronic and autoimmune disease cases, and a growing number of clinical trials in emerging regions. Collaborations between biotechnology firms and pharmaceutical companies also contribute significantly to this upward trend. Key developments in the upcoming years include the growth of bispecific and multispecific antibody technologies, expanding use of antibody-drug conjugates in cancer treatment, increased focus on antibodies with enhanced binding and extended activity, and a burgeoning clinical pipeline targeting rare and orphan diseases. Additionally, there is a clear shift towards personalized antibody therapies tailored to individual patient needs.

The next-generation antibody therapeutics market size has grown rapidly in recent years. It will grow from $7.56 billion in 2025 to $8.35 billion in 2026 at a compound annual growth rate (CAGR) of 10.4%. The growth in the historic period can be attributed to growth in monoclonal antibody approvals, increasing cancer prevalence, expansion of biologics manufacturing capacity, rising investment in pharmaceutical r&d, improved regulatory pathways for biologics.

Download a free sample of the next-generation antibody therapeutics market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12678&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Key Drivers Accelerating Demand in the Next-Generation Antibody Therapeutics Industry
One of the main factors propelling this market is the continuous innovation in antibody engineering techniques, allowing for more effective and targeted treatments. These technological advancements enable the creation of therapies that precisely attack disease cells while minimizing side effects.
Moreover, the growing prevalence of chronic illnesses and autoimmune disorders worldwide is increasing the demand for advanced antibody-based treatments. This rising health burden necessitates improved therapeutic options, thus driving the market's expansion.

Leading Companies Influencing the Next-Generation Antibody Therapeutics Market Landscape
The competitive landscape features several prominent players including Pfizer Inc., F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Amgen Inc., Regeneron Pharmaceuticals Inc., Biogen Inc., Genentech Inc., Kyowa Hakko Kirin Co. Ltd., Seagen Inc., Seattle Genetics Inc., Xencor Inc., ImmunoGen Inc., Genmab A/S, Zymeworks Inc., NBE-Therapeutics AG, Daiichi Sankyo Company Limited, Merck & Co Inc., Novartis AG, AbCellera Biologics Inc., Sotio Biotech, F-Star Therapeutics Ltd., ADC Therapeutics SA, and Harbour BioMed.
A notable industry development occurred in February 2024 when AbbVie Inc., a US-based pharmaceutical giant, acquired ImmunoGen, Inc. for approximately $10.1 billion. This strategic purchase aims to boost AbbVie's portfolio in next-generation antibody therapeutics by incorporating ImmunoGen's folate receptor-alpha-targeted antibody-drug conjugate, ELAHERE, which is approved for treating platinum-resistant ovarian cancer. The acquisition also helps AbbVie to broaden its pipeline of antibody-drug conjugates targeting both solid tumors and blood cancers. ImmunoGen, Inc. is a biotechnology firm based in the US, renowned for its cutting-edge antibody-drug conjugate platforms specifically developed for oncology.

View the full next-generation antibody therapeutics market report:
https://www.thebusinessresearchcompany.com/report/next-generation-antibody-therapeutics-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Recent Innovations and Technological Trends in Next-Generation Antibody Therapeutics
Industry players are focusing heavily on advanced technologies like Molecular Indexing of Proteins by Self-Assembly (MIPSA) to improve protein identification and characterization. This technology enhances the precision and effectiveness of treatments by enabling more detailed protein analysis, which helps in designing targeted therapies while potentially lowering costs.
For example, in January 2024, Infinity Bio, Inc., a US biotechnology company, introduced a next-generation antibody profiling platform that leverages MIPSA technology. This platform facilitates high-throughput and cost-efficient immune response analysis, aimed at deepening disease understanding and enabling personalized treatment approaches.

The Dominant Segments of the Next-Generation Antibody Therapeutics Market
This market is divided into key segments based on antibody types, therapeutic areas, and end users.
Types of antibodies include monoclonal antibodies, polyclonal antibodies, bispecific antibodies, antibody-drug conjugates, and other varieties such as nanobodies and engineered antibodies. Within monoclonal antibodies, subcategories include IgG and IgM types. Polyclonal antibodies are further classified into serum-derived and hybridoma-derived. Bispecific antibodies break down into dual-targeting antibodies and single-chain variable fragment (scFv) antibodies, while antibody-drug conjugates are segmented by targeted ADCs and payload types.
Therapeutic categories encompass oncology, autoimmune diseases, infectious diseases, neurodegenerative disorders, and other medical areas.
End users are primarily hospitals and clinics, research institutes, pharmaceutical and biotechnology companies, along with other relevant organizations.

Comprehensive Market Outlook and Future Directions
Looking ahead, the next-generation antibody therapeutics market is set to evolve with innovation and strategic collaborations at its core. The combination of rising disease incidence, technological advancements like MIPSA, and growing personalized treatment approaches will continue to shape market dynamics. This environment offers a fertile ground for both established pharmaceuticals and emerging biotech firms to capitalize on new opportunities while addressing unmet medical needs.

Our 2026 market reports now feature expanded strategic intelligence through market attractiveness scoring and analysis, total addressable market (TAM) analysis, company scoring matrix graphics and tables, Excel-based dashboards, market hotspots infographics, key technology and future trend analysis, along with updated graphics and tables.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.